Q-omics provides the consensus-scored RFX8 profile across patient tissues and cancer cell-line models. RFX8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RFX8 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, RFX8 RNA expression shows 17,945 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, HNSC, and BRCA as cancer lineages where RFX8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFX8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFX8 survival associations across molecular data types. RFX8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFX8 RNA expression–survival associations across cancer types. High RFX8 expression shows unfavorable associations in KIRP, OV, BLCA, STAD and LGG, but favorable associations in LAML. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for RFX8 RNA expression.
This table summarizes RFX8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RFX8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFX8 shows higher tumor expression in HNSC, KIRC, COAD, LUAD, LIHC and BLCA. The HNSC box plot shows higher RFX8 RNA expression in tumor versus normal tissue (log2 FC = +0.588, t-test p < 0.001).
This table shows molecular features associated with RFX8 in patient tissues and cancer cell lines. In patient samples, RFX8 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RFX8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
